

# NKI-AVL WEBINAR

INTRODUCTION IN CANCER DIAGNOSIS AND TREATMENT, INCLUDING IMMUNOTHERAPY AND TARGETED TREATMENT IN DIFFERENT CANCER TYPES AND THE ROLE OF NURSES AND NURSE PRACTITIONERS.

TUESDAY 31 MARCH 2026 (15:00 - 16:00HRS CEST)

## Empowering Nurses in Cancer Care: A Comprehensive Introduction

The Netherlands Cancer Institute – Antoni van Leeuwenhoek (NKI-AVL) is proud to present a series of webinars designed to equip healthcare professionals with essential knowledge and skills in cancer diagnosis and treatment. Tailored for nurses, nurse practitioners, and paramedics, these courses address the unique challenges in understanding and applying cutting-edge oncology practices, including immunotherapy (IT) and targeted therapies (TT).

Nurses and nurse practitioners play a vital role in managing patients receiving cancer treatment. This programme highlights their contributions in clinical support, patient education, and the management of side effects, empowering participants to enhance patient outcomes effectively.

Key Learning Objectives:

- Understand the fundamentals of cancer diagnosis, staging, and treatment, including TT, IT, and cell therapies.
- Explore treatment approaches for melanoma and renal cell cancer.
- Recognise the benefits of TT and IT in improving survival and quality of life.
- Identify and manage adverse events related to modern cancer therapies.
- Learn the principles of genetic sequencing, biomarker testing, and molecular imaging techniques.
- Gain insights into the evolving role of nurses in oncology care, informed by real-world expertise at NKI-AVL.

Join us in this engaging webinar series to build a strong foundation in oncology care and support patients through innovative therapies.

We look forward to having you join us.

The Netherlands Cancer Institute-Antoni van Leeuwenhoek  
Amsterdam, The Netherlands

## PROGRAMME HIGHLIGHTS

TUESDAY, 31 MARCH FROM 15:00 - 16:00HRS CEST

- **Radionuclide Therapy Imaging, Targeting, Treating: Theranostics as treatment option in oncology by Michelle Versleijen, Nuclear Medicine Physician, NKI-AVL.**

Radionuclide therapy has become an important treatment option in several cancer types, like prostate cancer, thyroid cancer and neuroendocrine tumors. By targeting specific features expressed on cancer cells with radiolabeled carriers it is possible to visualize and stage tumors, the diagnostic part. By using different radionuclides, but using the same carrier, it becomes possible to irradiate the tumor deposits, the therapeutic part. The combination of the therapeutic and diagnostic parts is called “Theranostics”. In this webinar, an overview is given on the basic principles, clinical applications and outcomes of this new treatment option in oncology.

- **Theranostics in Clinical Practice by Kelly van Harinxma, Physician Assistant, NKI-AVL.**

Radionuclide therapy is booming business, but it requires a thorough patient selection and preparation prior to treatment. The treatment itself is on an in-patient base in special rooms built for radionuclide therapy. During admission, contamination and early side-effects may occur, whereas after discharge late side-effects, such as bone myelosuppression and renal failure, can be observed. Finally, patients may have to follow specific rules and regulations after discharge due to the radiation emitted. These practical aspects will be discussed in the second part with focus on the role of nurses and PAs.

Moderator: Marcel Stokkel, Dean AVL Academy

## WHO ARE THESE WEBINARS ORGANISED FOR?

These webinars are organised for healthcare professionals, like nurses, nurse practitioners, paramedics.

## MORE INFORMATION

<https://www.avl.nl/agenda/2026/webinar/>

